Lehman Brothers upgraded D&K Healthcare (DKWD) to strong buy from buy.
Analyst Lawrence Marsh says his upgrade is based on continued expansion in the rate of growth, and is benefiting from additional capital and a broadening customer base. He sees opportunities to expand management ranks over the next few months, benefiting from further consolidation in the industry. He notes good margin expansion opportunities off a lower base vs. the industry average, leading to faster growth prospects vs. its larger peers. Finally Marsh says shares are off 15% from its recent high, despite better than expected second quarter results. He raised his $66 one-year target to $70.